The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study-Reference-Cited by-同舟云学术

The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study

Published:2021-12-21 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Badawy Sherif M.¹²^ORCID,Kattamis Antonis³^ORCID,Ezzat Hatoon⁴,Deschamps Benoît⁵,Sicard Eric⁵,Fradette Caroline⁶,Zhao Feng⁶,Tricta Fernando⁶,Chung Tsang Yu⁷,Sheth Sujit⁸,Piga Antonio⁹

Affiliation:

1. Ann & Robert H. Lurie Children’s Hospital of Chicago Chicago Illinois USA

2. Northwestern University Feinberg School of Medicine Chicago Illinois USA

3. National and Kapodistrian University of Athens‘Aghia Sophia’ Children’s Hospital Athens Greece

4. St Paul's Hospital Vancouver British Columbia Canada

5. Altasciences Montreal Quebec Canada

6. Chiesi Canada Corporation Toronto Ontario Canada

7. Apotex Inc Toronto Ontario Canada

8. New York Presbyterian Hospital/Weill Cornell Medical College New York New York USA

9. University of Turin Turin Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17999

Reference15 articles.

1. Thalassaemia

2. β-Thalassemias

3. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications

4. Iron caught on the shuttle

5. Electronic Medicines Compendium (EMC).Ferriprox 500mg film‐coated tablets. Summary of product characteristics. Available from:https://www.medicines.org.uk/emc/product/10908/smpcAccessed 31 August 2020.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world evidence: Long‐term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years;American Journal of Hematology;2024-03

2. Adherence to Iron Chelation Therapy Among Children with Beta Thalassemia Major: A Multicenter Cross-Sectional Study;Hemoglobin;2023-11-02

3. Combination chelation therapy;Annals of the New York Academy of Sciences;2023-08-18

4. Clinical Challenges with Iron Chelation in Beta Thalassemia;Hematology/Oncology Clinics of North America;2023-04

5. Deferiprone and Iron–Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects;International Journal of Molecular Sciences;2023-03-04